Irritable Bowel Syndrome

Adhering to a greater number of healthy lifestyle behaviors was linked to a decreased risk of incident IBS, suggesting lifestyle modifications may help prevent its onset.

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with UC and decreased C-reactive protein levels in patients with CD.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

Presented at United European Gastroenterology Week 2023, results of the retrospective study showed ferric maltol was safe for us in pregnant patients with IBD and iron deficiency anemia.

Presented in an abstract at ACG 2023, filgotinib missed both co-primary endpoints at week 10 but was efficacious at week 52 in the maintenance cohorts.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

Screen time ≥2 hours/day at 8 years of age was associated with an increased risk of developing IBD.

The role of psychiatric care may be understated in treating IBD in children and adolescents nearing adult age.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

The features of pediatric IBD can be non-specific, but there are signs in biopsies and clinical history that may indicate what is and isn't IBD.

Major advances to biomarkers, targeted therapies and a modernized care team could help IBD specialists achieve a more nuanced care strategy for children.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Results from both studies showed the safety of filgotinib for the treatment of ulcerative colitis compared to placebo treatment groups.

Nearly half of patients with IBD in remission experienced abdominal pain, which was associated with sex, fatigue, and depressive symptoms.

The greatest level of treatment discontinuation was seen among patients aged 18-24 years, highlighting an increased risk of early disease relapse.

The potassium-competitive acid blocker drug class is coming to US digestive disease management. How does it fare to standard antacids and PPIs for GERD?

Analysis showed a higher proportion of patients with CD with NAFLD, varying across studies and regions.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

A population-based cohort study highlighted an association between AD and IBD with risk varying by age, AD severity, and subtype of IBD.

Findings from a recent study of patients with IBD on biologic therapy suggest selenium and zinc deficiencies may predict disease outcomes and adverse clinical effects.

Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.

When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.